AMNEAL PHARMACEUTICALS, INC. Royalty Expense
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Royalty Expense of $1.97 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2024-11-12
- AMNEAL PHARMACEUTICALS, INC. royalty expense for the quarter ending 2024-09-30 was $1.97M, a 122.01% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. royalty expense for the quarter ending 2024-06-30 was $1.04M, a 27.07% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. royalty expense for the quarter ending 2024-03-31 was $984.00K, a 40.15% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. royalty expense for the quarter ending 2023-12-31 was $478.00K, a 64.90% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. royalty expense for fiscal 2023 was $3.83M, a 12.16% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. royalty expense for fiscal 2022 was $4.36M, a 43.52% decline from fiscal 2021.
- AMNEAL PHARMACEUTICALS, INC. royalty expense for fiscal 2021 was $7.72M, a 27.58% decline from fiscal 2020.
- AMNEAL PHARMACEUTICALS, INC. royalty expense for fiscal 2020 was $10.65M, a 25.17% decline from fiscal 2019.
| Period end | Royalty Expense 3 month | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $1.97M 10-Q · filed 2024-11-12 | $3.01M derived: sum of 2 quarters · filed 2024-11-12 | $3.99M 10-Q · filed 2024-11-12 | $4.47M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | $1.04M 10-Q · filed 2024-08-09 | $2.03M 10-Q · filed 2024-08-09 | $2.50M derived: sum of 3 quarters · filed 2024-08-09 | $3.39M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-03-31 | $984.00K 10-Q · filed 2024-05-08 | $1.46M derived: sum of 2 quarters · filed 2024-05-08 | $2.35M derived: sum of 3 quarters · filed 2024-11-12 | $3.17M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-12-31 | $478.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.36M derived: sum of 2 quarters · filed 2024-11-12 | $2.18M derived: sum of 3 quarters · filed 2024-11-12 | $3.83M 10-K · filed 2024-03-14 |
| 2023-09-30 | $886.00K 10-Q · filed 2024-11-12 | $1.71M derived: sum of 2 quarters · filed 2024-11-12 | $3.35M 10-Q · filed 2024-11-12 | $4.71M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $820.00K 10-Q · filed 2024-08-09 | $2.46M 10-Q · filed 2024-08-09 | $3.83M derived: sum of 3 quarters · filed 2024-08-09 | $5.24M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $1.64M 10-Q · filed 2024-05-08 | $3.01M derived: sum of 2 quarters · filed 2024-05-08 | $4.42M derived: sum of 3 quarters · filed 2024-05-08 | $5.24M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $2.77M derived: sum of 2 quarters · filed 2024-03-14 | $3.59M derived: sum of 3 quarters · filed 2024-03-14 | $4.36M 10-K · filed 2024-03-14 |
| 2022-09-30 | $1.41M 10-Q · filed 2023-11-09 | $2.23M derived: sum of 2 quarters · filed 2023-11-09 | $3.00M 10-Q · filed 2023-11-09 | $4.14M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $821.00K 10-Q · filed 2023-08-08 | $1.58M 10-Q · filed 2023-08-08 | $2.73M derived: sum of 3 quarters · filed 2024-03-14 | $4.35M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $764.00K 10-Q · filed 2023-05-09 | $1.91M derived: sum of 2 quarters · filed 2024-03-14 | $3.53M derived: sum of 3 quarters · filed 2024-03-14 | $4.90M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $2.77M derived: sum of 2 quarters · filed 2024-03-14 | $4.13M derived: sum of 3 quarters · filed 2024-03-14 | $7.72M 10-K · filed 2024-03-14 |
| 2021-09-30 | $1.63M 10-Q · filed 2022-11-07 | $2.99M derived: sum of 2 quarters · filed 2022-11-07 | $6.57M 10-Q · filed 2022-11-07 | $10.28M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $1.36M 10-Q · filed 2022-08-08 | $4.95M 10-Q · filed 2022-08-08 | $8.65M derived: sum of 3 quarters · filed 2023-03-03 | $10.78M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $3.58M 10-Q · filed 2022-05-06 | $7.28M derived: sum of 2 quarters · filed 2023-03-03 | $9.42M derived: sum of 3 quarters · filed 2023-03-03 | $12.97M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $5.83M derived: sum of 2 quarters · filed 2023-03-03 | $9.38M derived: sum of 3 quarters · filed 2023-03-03 | $10.65M 10-K · filed 2023-03-03 |
| 2020-09-30 | $2.13M 10-Q · filed 2021-11-08 | $5.68M derived: sum of 2 quarters · filed 2021-11-08 | $6.95M 10-Q · filed 2021-11-08 | $11.93M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $3.55M 10-Q · filed 2021-08-09 | $4.82M 10-Q · filed 2021-08-09 | $9.79M derived: sum of 3 quarters · filed 2022-03-01 | $12.38M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $1.27M 10-Q · filed 2021-05-07 | $6.25M derived: sum of 2 quarters · filed 2022-03-01 | $8.83M derived: sum of 3 quarters · filed 2022-03-01 | $11.34M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $4.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $7.56M derived: sum of 2 quarters · filed 2022-03-01 | $10.07M derived: sum of 3 quarters · filed 2022-03-01 | $14.24M 10-K · filed 2022-03-01 |
| 2019-09-30 | $2.59M 10-Q · filed 2020-11-06 | $5.10M derived: sum of 2 quarters · filed 2020-11-06 | $9.26M 10-Q · filed 2020-11-06 | $12.50M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $2.51M 10-Q · filed 2020-08-06 | $6.68M 10-Q · filed 2020-08-06 | $9.91M derived: sum of 3 quarters · filed 2021-03-01 | $14.31M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $4.17M 10-Q · filed 2020-05-11 | $7.40M derived: sum of 2 quarters · filed 2021-03-01 | $11.80M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | $3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $7.64M derived: sum of 2 quarters · filed 2021-03-01 | $16.26M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $4.40M 10-Q · filed 2019-11-07 | $13.02M 10-Q · filed 2019-11-07 | ||
| 2017-12-31 | $20.52M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |